Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB

Leukemia Research

Volumn 34, Issue 1, 2010, Pages 77-84

  Erikstein, Bjarte Skoe ^a   McCormack, Emmet ^a,b   Tronstad, Karl Johan ^a   Schwede, Frank ^c   Berge, Rolf ^a   Gjertsen, Bjørn Tore ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c BIOLOG Life Science Institute   (Germany)

Author keywords

Acute myelogenous leukaemia; Bcl 2; cAMP response element binding; Cyclic AMP; Inducible cAMP early repressor; Peroxisome proliferator activated receptor; Protein kinase A; Tetradecylthioacetic acid

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; ANTILEUKEMIC AGENT; BUTYRYL CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ACTIVATOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN BCL 2; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG SYNERGISM; ENZYME ACTIVATORS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RATS; SULFIDES;

EID: 73249143661     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.005     Document Type: Article

References (46)

1. Erba H.P. Prognostic factors in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program 2007 (2007) 420-428
2. Tronstad K.J., Berge K., Berge R.K., and Bruserud O. Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opin Ther Targets 7 (2003) 663-677
3. McCubrey J.A., Steelman L.S., Abrams S.L., Bertrand F.E., Ludwig D.E., Basecke J., et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22 (2008) 708-722
4. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., and Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6 (2007) 793-810
5. Berge R.K., Tronstad K.J., Berge K., Rost T.H., Wergedahl H., Gudbrandsen O.A., et al. The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 87 (2005) 15-20
6. Kopperud R., Krakstad C., Selheim F., and Doskeland S.O. cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett 546 (2003) 121-126
7. Ruchaud S., Seite P., Foulkes N.S., Sassone-Corsi P., and Lanotte M. The transcriptional repressor ICER and cAMP-induced programmed cell death. Oncogene 15 (1997) 827-836
8. Kobsar A., Heeg S., Krohne K., Opitz A., Walter U., Bock M., et al. Cyclic nucleotide-regulated proliferation and differentiation vary in human hematopoietic progenitor cells derived from healthy persons, tumor patients, and chronic myelocytic leukemia patients. Stem Cells Dev 17 (2008) 81-91
9. Rossi A.G., Cousin J.M., Dransfield I., Lawson M.F., Chilvers E.R., and Haslett C. Agents that elevate cAMP inhibit human neutrophil apoptosis. Biochem Biophys Res Commun 217 (1995) 892-899
10. Hermouet S., and Lanotte M. Cholera toxin resistance associated with deficient adenylate-cyclase activity in a subclone of the rat promyelocytic leukemia (BNML). Leukemia 3 (1989) 289-293
11. Gjertsen B.T., Cressey L.I., Ruchaud S., Houge G., Lanotte M., and Doskeland S.O. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. J Cell Sci 107 (1994) 3363-3377
12. Cho Y.J., Kim J.Y., Jeong S.W., Lee S.B., and Kim O.N. Cyclic AMP induces activation of extracellular signal-regulated kinases in HL-60 cells: role in cAMP-induced differentiation. Leuk Res 27 (2003) 51-56
13. Zhang L., and Insel P.A. The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells. J Biol Chem 279 (2004) 20858-20865
14. Zhu Q., Zhang J.W., Zhu H.Q., Shen Y.L., Flexor M., Jia P.M., et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99 (2002) 1014-1022
15. Tronstad K.J., Bruserud O., Berge K., and Berge R.K. Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia 16 (2002) 2292-2301
16. Tronstad K.J., Gjertsen B.T., Krakstad C., Berge K., Brustugun O.T., Doskeland S.O., et al. Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chem Biol 10 (2003) 609-618
17. Berge K., Tronstad K.J., Flindt E.N., Rasmussen T.H., Madsen L., Kristiansen K., et al. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22 (2001) 1747-1755
18. Iversen P.O., Sorensen D.R., Tronstad K.J., Gudbrandsen O.A., Rustan A.C., Berge R.K., et al. A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clin Cancer Res 12 (2006) 3525-3531
19. Madsen L., Guerre-Millo M., Flindt E.N., Berge K., Tronstad K.J., Bergene E., et al. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J Lipid Res 43 (2002) 742-750
20. Grav H.J., Tronstad K.J., Gudbrandsen O.A., Berge K., Fladmark K.E., Martinsen T.C., et al. Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression. J Biol Chem 278 (2003) 30525-30533
21. Bivol L.M., Berge R.K., and Iversen B.M. Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension. Am J Physiol Regul Integr Comp Physiol 294 (2008) 438-447
22. Pettersen R.J., Salem M., Skorve J., Ulvik R.J., and Berge R.K. Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study. J Cardiovasc Pharmacol 51 (2008) 410-417
23. Fox K.E., Fankell D.M., Erickson P.F., Majka S.M., Crossno Jr. J.T., and Klemm D.J. Depletion of cAMP-response element-binding protein/ATF1 inhibits adipogenic conversion of 3T3-L1 cells ectopically expressing CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBP beta, or PPAR gamma 2. J Biol Chem 281 (2006) 40341-40353
24. Sweet S., and Singh G. Changes in mitochondrial mass, membrane potential, and cellular adenosine triphosphate content during the cell cycle of human leukemic (HL-60) cells. J Cell Physiol 180 (1999) 91-96
25. Seite P., Ruchaud S., Hillion J., Gendron M.C., Bruland O., Segal-Bendirdjian E., et al. Ectopic expression of Bcl-2 switches over nuclear signalling for cAMP-induced apoptosis to granulocytic differentiation. Cell Death Differ 7 (2000) 1081-1089
26. Christensen A.E., Selheim F., de Rooij J., Dremier S., Schwede F., Dao K.K., et al. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 278 (2003) 35394-35402
27. Schwede F., Christensen A., Liauw S., Hippe T., Kopperud R., Jastorff B., et al. 8-Substituted cAMP analogues reveal marked differences in adaptability, hydrogen bonding, and charge accommodation between homologous binding sites (AI/AII and BI/BII) in cAMP kinase I and II. Biochemistry 39 (2000) 8803-8812
28. Spydevold O., and Bremer J. Induction of peroxisomal beta-oxidation in 7800 C1 Morris hepatoma cells in steady state by fatty acids and fatty acid analogues. Biochim Biophys Acta 1003 (1989) 72-79
29. Bartsch M., Zorn-Kruppa M., Kuhl N., Genieser H.G., Schwede F., and Jastorff B. Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells. Biol Chem 384 (2003) 1321-1326
30. Fields R.D., and Lancaster M.V. Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am Biotechnol Lab 11 (1993) 48-50
31. O'Brien J., Wilson I., Orton T., and Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267 (2000) 5421-5426
32. Bruserud O., Hovland R., Wergeland L., Huang T.S., and Gjertsen B.T. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88 (2003) 416-428
33. Wergeland L., Sjoholt G., Haaland I., Hovland R., Bruserud O., and Gjertsen B.T. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer 6 (2007) 33
34. Billes S.K., and Cowley M.A. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 32 (2007) 822-834
35. Slinker B.K. The statistics of synergism. J Mol Cell Cardiol 30 (1998) 723-731
36. McCormack E., Bruserud O., and Gjertsen B.T. Animal models of acute myelogenous leukaemia-development, application and future perspectives. Leukemia 19 (2005) 687-706
37. Ahmed S.A., Gogal R.M., and Walsh J.E. A new rapid and simple nonradioactive assay to monitor and determine the proliferation of lymphocytes-an alternative to [H-3]thymidine incorporation assay. J Immunol Methods 170 (1994) 211-224
38. Laxman S., Riechers A., Sadilek M., Schwede F., and Beavo J.A. Hydrolysis products of cAMP analogs cause transformation of Trypanosoma brucei from slender to stumpy-like forms. Proc Natl Acad Sci USA 103 (2006) 19194-19199
39. Chan S.L., and Yu V.C. Proteins of the Bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 31 (2004) 119-128
40. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
41. van Bekkum D.W., and Hagenbeek A. Relevance of the BN leukemia as a model for human acute myeloid leukemia. Blood Cells 3 (1977) 565-667
42. Einsiedel H.G., Kawan L., Eckert C., Witt O., Fichtner I., Henze G., et al. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 20 (2006) 1435-1436
43. Taimi M., Breitman T.R., and Takahashi N. Cyclic AMP-dependent protein kinase isoenzymes in human myeloid leukemia (HL60) and breast tumor (MCF-7) cells. Arch Biochem Biophys 392 (2001) 137-144
44. Selvakumar E., and Hsieh T.C. Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by lipoic acid: role in cancer prevention and therapy. J Hematol Oncol 1 (2008) 4
45. Ginsberg M.D., Feliciello A., Jones J.K., Avvedimento E.V., and Gottesman M.E. PKA-dependent binding of mRNA to the mitochondrial AKAP121 protein. J Mol Biol 327 (2003) 885-897
46. Connolly B.J., Willits P.B., Warrington B.H., and Murray K.J. 8-(4-Chlorophenyl)thio-cyclic AMP is a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA). Biochem Pharmacol 44 (1992) 2303-2306